Objective. To increase physicians' and dentists' awareness that nicorandil
is a potential inducer of severe mouth ulceration.
Study design. Nine new cases of ulceration from 3 European countries were i
ncluded in this study.
Results. Oral ulceration developed within 9 months of beginning nicorandil
therapy, and ulcers resolved within 1 month of withdrawal of the drug. No l
esions developed on other epithelia.
Conclusions. A number of drugs used in the care of patients with cardiovasc
ular disease can cause oral adverse effects. Nicorandil, a new potassium-ch
annel activator used in some countries to treat angina pectoris, precipitat
es persistent ulcerative stomatitis in some patients.